Physician profile
Wendy Patricia Almonte
NPI 1558031054
$10,665.36
in general payments reported to CMS, 2019-2025
32 companies · $4,321 in 2025
The $4,321 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $831 · 2023: $1,784 · 2024: $3,629 · 2025: $4,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,565 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,564.97 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,997.13 | 2021-2025 | |
| Janssen Biotech, INC. | $1,768.70 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,140.17 | 2022-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $720.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $628.37 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $563.22 | 2024-2025 | Livdelzi, Vemlidy, Epclusa |
| Lilly USA, LLC | $484.93 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $401.27 | 2024-2025 | Voquezna |
| Genzyme Corporation | $347.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $331.36 | 2022-2025 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $270.12 | 2022-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $244.16 | 2022-2025 | Entyvio |
| Qol Medical, LLC | $224.82 | 2024-2025 | Sucraid, Sucraid |
| Exact Sciences Corporation | $215.40 | 2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $209.26 | 2024-2025 | Vowst |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $144.07 | 2022-2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $142.57 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $128.43 | 2023 | |
| Pfizer INC. | $127.28 | 2025 | |
| Edwards Lifesciences Corporation | $115.69 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Intercept Pharmaceuticals, INC. | $94.82 | 2022-2024 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.73 | 2023-2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $64.38 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $56.92 | 2022-2023 | Recarbrio, Zerbaxa, Dificid |
| United Therapeutics Corporation | $31.31 | 2022 | |
| Bard Peripheral Vascular, INC. | $31.15 | 2022-2025 | Lifestream |
| Pentax of America, INC. | $21.82 | 2023 | N/A |
| Philips North America LLC | $20.43 | 2025 | Vest Therapy Und |
| Incyte Corporation | $19.69 | 2021 | |
| Braintree Laboratories, INC. | $15.18 | 2023 | Sutab |
| Epi Health, LLC | $15.11 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Almonte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.